Sarepta Therapeutics Elects Biopharmaceutical Veteran, Michael W. Bonney, to its Board of Directors
06 December 2017 - 12:30AM
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage
biopharmaceutical company focused on the discovery and development
of precision genetic medicines to treat rare neuromuscular
diseases, today announced the election of biopharmaceutical veteran
Michael W. Bonney to its board of directors.
From 2003 through its acquisition by Merck in
2014, Mr. Bonney was the chief executive officer of Cubist
Pharmaceuticals. Mr. Bonney is currently the chief executive
officer and chair of Kaleido Biosciences, a biotechnology company
focused on the development of novel chemistries to unlock the power
of the human microbiome. He also serves as chair of the boards of
Alnylam Pharmaceuticals, Inc. and Magenta Therapeutics, is a member
of the board for Celgene Corporation and a former partner at Third
Rock Ventures. Additionally, Mr. Bonney is a trustee of the four
healthcare dedicated closed end mutual funds managed by Tekla
Capital Management.
“Sarepta and its board of directors are greatly
enhanced with the appointment to our board of Mike Bonney, one of
the most respected biopharmaceutical leaders,” said M. Kathleen
Behrens, Ph.D., chair of Sarepta’s board of directors. “Mike’s list
of accomplishments is long and his impact on this industry has been
profound. We will leverage Mike’s experience as we execute our
mission to improve the lives of those suffering from rare
diseases.”
“Sarepta stands at a moment of great inflection
as we continue the successful launch of our first therapy for the
treatment of Duchenne muscular dystrophy while accelerating with a
sense of urgency our rich precision genetic medicine pipeline,”
said Douglas Ingram, Sarepta’s president and chief executive
officer. “I am fortunate to have access to the insight and guidance
of someone of Mike’s impeccable credentials and nearly unique
experience across all aspects of the biopharmaceutical ecosystem as
we execute our ambitious plan and fulfil our important commitments
to our patients.”
“Sarepta’s mission and technology are critically
important for children with DMD, their families and potentially a
range of patients living with other diseases,” said Mr. Bonney. “I
am delighted to apply my experience to help the company realize its
goal to make an important impact for these underserved patient
populations.”
About Sarepta Therapeutics
Sarepta Therapeutics is a commercial-stage
biopharmaceutical company focused on the discovery and development
of precision genetic medicines to treat rare neuromuscular
diseases. The Company is primarily focused on rapidly advancing the
development of its potentially disease-modifying Duchenne muscular
dystrophy (DMD) drug candidates. For more information, please visit
www.sarepta.com.
Forward-Looking Statements
This press release contains forward-looking
statements. Any statements contained in this press release that are
not statements of historical fact may be deemed to be
forward-looking statements. Words such as "believes,"
"anticipates," "plans," "expects," "will," "intends," "potential,"
"possible" and similar expressions are intended to identify
forward-looking statements. These forward-looking statements
include statements regarding Sarepta’s plan to leverage Mr.
Bonney’s experience as it executes its mission to improve the lives
of those suffering from rare disease; Sarepta’s plan to continue
the successful launch of its first therapy for the treatment of DMD
while accelerating with a sense of urgency Sarepta’s rich precision
genetic medicine pipeline; Mr. Bonney’s credential and experience
being invaluable to Sarepta as it executes its ambitious plan and
fulfils its important commitment to its patients; Sarepta’s mission
and technology being critically important for children with DMD,
their families and potentially a range of patients living with
other diseases; and Mr. Bonney’s intent to apply his experience to
help Sarepta realize its goal to make an important impact for these
underserved patient population.
These forward-looking statements involve risks
and uncertainties, many of which are beyond Sarepta’s control.
Known risk factors include, among others: Sarepta may not be able
to meet expectations with respect to the sales of its first therapy
for the treatment of DMD; Sarepta may not be able to complete
clinical trials required by the FDA or other regulatory authorities
for approval of any of its product candidates; the results of
Sarepta’s ongoing research and development efforts and clinical
trials for its product candidates may not be positive or consistent
with prior results or demonstrate a safe treatment benefit; Sarepta
may not be able to execute on its business plans, including meeting
its expected or planned regulatory milestones and timelines,
clinical development plans, and bringing its products to U.S. and
ex-U.S. markets for various reasons including possible limitations
of company financial and other resources, manufacturing limitations
that may not be anticipated or resolved for in a timely manner, and
regulatory, court or agency decisions, such as decisions by the
United States Patent and Trademark Office with respect to patents
that cover Sarepta’s product candidates; and those risks identified
under the heading “Risk Factors” in Sarepta’s most recent Annual
Report on Form 10-K for the year ended December 31, 2016 and most
recent Quarterly Report on Form 10-Q filed with the Securities and
Exchange Commission (SEC) as well as other SEC filings made by the
Company which you are encouraged to review.
Any of the foregoing risks could materially and
adversely affect the Company’s business, results of operations and
the trading price of Sarepta’s common stock. For a detailed
description of risks and uncertainties Sarepta faces, you are
encouraged to review Sarepta's 2016 Annual Report on Form 10-K and
most recent Quarterly Report on Form 10-Q for the quarter ended
September 30, 2017 filed with the Securities and Exchange
Commission (SEC) as well as other SEC filings made by Sarepta. We
caution investors not to place considerable reliance on the
forward-looking statements contained in this press release. Sarepta
does not undertake any obligation to publicly update its
forward-looking statements based on events or circumstances after
the date hereof.
Internet Posting of
Information
We routinely post information that may be
important to investors in the 'For Investors' section of our
website at www.sarepta.com. We encourage investors and
potential investors to consult our website regularly for important
information about us.
Source: Sarepta Therapeutics, Inc.
Media and Investors: Sarepta Therapeutics, Inc. Ian Estepan,
617-274-4052 iestepan@sarepta.com or W2O Group Brian Reid,
212-257-6725 breid@w2ogroup.com
Sarepta Therapeutics (NASDAQ:SRPT)
Historical Stock Chart
From Apr 2024 to May 2024
Sarepta Therapeutics (NASDAQ:SRPT)
Historical Stock Chart
From May 2023 to May 2024